Дорофеева Г.Б., Дорофеев И.В.,Трофимова Ю.В. Патогенетические особенности развития артериальной гипертензии в менопаузе у женщин и возможности ее коррекции. Consilium Medicum. 2014; 16 (1): 12–16.
Патогенетические особенности развития артериальной гипертензии в менопаузе у женщин и возможности ее коррекции
Дорофеева Г.Б., Дорофеев И.В.,Трофимова Ю.В. Патогенетические особенности развития артериальной гипертензии в менопаузе у женщин и возможности ее коррекции. Consilium Medicum. 2014; 16 (1): 12–16.
1. Mendelsohn M, Karas R. The protective effects of estrogen on cardiovascular system. N Engl J Med 1999; 34: 1801–1.
2. Bolego C, Cignarella A, Sanvito P et al. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-α agonists and is abolished by estrogen deprivation. J Pharm And Exp Ther 2005; 313: 1203–8.
3. Hodgin JB, Knowles JW, Kim HS et al. Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice. J Clin Invest 2002; 109 (4): 541–8.
4. Saitta A, Altavilla D, Cucinotta D et al. Randomized, double-blind, placebo-controlled Study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512–8.
5. Cox MW, Fu W, Chai H et al. Effects of progesterone and estrogen on endothelial dysfunction in porcine coronary arteries. J Surg Res 2005; 124 (1): 104–11.
6. Santos RL, Abreu GR, Bissoli NS et al. Endothelial mediators of 17b-estradiol-induced coronary vasodilation in the isolated rat heart. Braz J Med Biol Res 2004; 37 (4): 569–75.
7. Tostes RC, Nigro D, Fortes ZB et al. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003; 36 (9): 1143–58.
8. Mikkola T, Viinikka L, Ylkorkala O. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil Steril 2000; 73 (1): 72–4.
9. Moyses MR, Barker LA, Cabral AM. Sex hormone modulation of serotonin-induced coronary vasodilation in isolated heart. Braz J Med Biol Res 2001; 34 (7): 949–58.
10. Ma L, Yu Z, Xiao S et al. Supersensitivity to serotonin- and histamine-induced arterial contraction following ovariectomy. Eur J Pharmacol 1998; 359 (2): 191–200.
11. David FL, Carvalho MH, Cobra AL et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001; 38 (2): 692–6.
12. Polderman KH, Stehouwer CD, van Kamp GJ et al. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 2000; 49 (5): 648–50.
13. Patterson E, Ma L, Szabo B et al. Ovariectomy and estrogen-induced alterations in myocardial contractility in female rabbits: role of the L-type calcium channel. Pharm Еxp Тher 1998; 284 (2): 586–91.
14. Bednarek-Tupikowska G. Antioxidant properties of estrogens. Ginekol Pol 2002; 73 (1): 61–7.
15. Ruiz-Larrea MB, Martin C, Martinez R et al. Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids 2000; 105 (2): 179–88.
16. Reyes MR, Sifuentes-Alvarez A, Lazalde B. Estrogens are potentially the only steroids with an antioxidant role in pregnancy: in vitro evidence. Acta Obstet Gynecol Scand 2006; 85 (9): 1090–3.
17. Krstevska M, Dzhekova-Stojkova S, Bosilkova G. Menopause, coronary artery disease and antioxidants. Clin Chem Lab Med 2001; 39 (7): 641–4.
18. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 2005; 97 (10): 1046–54.
19. Delibasi T, Kockar C, Celik A et al. Antioxidant effects of hormone replacement therapy in postmenopausal women. Swiss Med Wkly 2006; 136 (31): 510–4.
20. Shelley JM, Green A, Smith AM et al. Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol 1998; 8: 39–45.
21. Ceconi C, Francolini G, Bastianon D et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis in vivo and in vivo studies. Cardovasc Drugs Ther 2007; 21: 423–9.
22. Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther 2007; 21 (4): 269–79.
23. Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18 (10): 2766–72.
24. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113: NA.
25. Мычка В.Б., Жернакова Ю.В., Чазова И.Е. Улучшенная форма Периндоприла – пРЕстариуМ А – в лечении больных артерИальной гипертонией в различных клинических ситуациЯх (ПРЕМИЯ). Системные гипертензии. 2009; 4: 50–3.
26. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Prefer redreporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12.
27. Jandrain B et al. Long-term acceptability of perindopril in type II diabetic patients with hypertension. Am J Med 1992; 92: 91–4.
28. Andrejak M et al. A double-blind comparison of perindopril and HCTZ-amiloride in mild to moderate essential hypertension. Fundam Clin Pharmacol 1991; 5: 185–92.
29. Мычка В.Б., Масенко В.П., Творогова М.Г. и др. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия. 2002; 8 (1): 16.
30. Fogari R, Zoppi A, Lazzari P et al. ACE Inhibition But Not Angiotensin II Antagonism Reduces Plasma Fibrinogen and Insulin Resistance inOverweight Hypertensive Patients. J Cardiovasc Pharmacol 1998; 32 (4): 616–20.
31. Недогода С.В., Морозова Т.Е. Возможности коррекции нарушений липидного обмена ингибиторами ангиотензинпревращающего фермента в условиях реальной практики. Cons. Med. Кардиология (Прил.). 2012; 14 (1): 3–6.
Авторы
Г.Б.Дорофеева, И.В.Дорофеев, Ю.В.Трофимова
ГБОУ ВПО Северо-Западный государственный медицинский университет им. И.И.Мечникова Минздрава России, Санкт-